Uncategorized

Madrigal Pharmaceuticals Announces Pricing of Upsized $600 Million Public Offering

Madrigal Pharmaceuticals, Inc. announced the pricing of its underwritten public offering of 750,000 shares of its common stock at a public offering price of $260.0000 per share, and, to certain investors, pre-funded warrants to purchase 1,557,692 shares of common stock at a price of $259.9999 per pre-funded warrant, which represents the per share public offering

Madrigal Pharmaceuticals Announces Pricing of Upsized $600 Million Public Offering Read More »

Cognizant to apply generative AI to enhance drug discovery for pharmaceutical clients with NVIDIA BioNeMo

Cognizant is advancing the application of generative AI technology with the NVIDIA BioNeMo platform to solve complex challenges of drug discovery in the life sciences industry, such as improving productivity in the development process and increasing the speed at which new, life-saving treatments can be brought to market.

Cognizant to apply generative AI to enhance drug discovery for pharmaceutical clients with NVIDIA BioNeMo Read More »

Scroll to Top